$0.89
−1.34%Price chart
Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29
Key dataOct 29, 2026
Open$0.92
From 52W high−84.93%
Volume179340.00
Market cap$90.42M
P/E (TTM)—
P/S (TTM)3.6x
Div yield—
Key dataOct 29, 2026
Open
$0.92
From 52W high
−84.93%
Volume
179340.00
Market cap
$90.42M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
P/E (TTM)
—
RSI (14)
31.1
MomentumView details →
1D Return
−1.34%
YTD Return
−80.26%
SummaryUpdated Jun 1, 2026
Nyxoah S.A. (NASDAQ:NYXH) is a Belgian medical technology company founded in 2009 and headquartered in Mont-Saint-Guibert, Belgium. The company went public on NASDAQ in April 2021, focusing on developing innovative solutions for sleep-disordered breathing conditions. Nyxoah has established itself as a challenger in the hypoglossal nerve stimulation market, primarily competing against established players like Inspire Medical Systems. The company has achieved commercial success in Europe, particularly Germany, and is preparing for its U.S. market launch following anticipated FDA approval in early 2025.
Similar companies
Latest newsMore news →
Nyxoah announced that it will release its third-quarter 2026 financial results on November 5, 2026.3d agoNyxoah reported preliminary unaudited third-quarter 2026 global net revenue of approximately €9.2 million, up 19% sequentially, and U.S. net revenue of approximately €6.7 million, up 29% sequentially.11d agoNyxoah submitted a PMA supplement to the FDA to expand Genio's U.S. indication to patients with Complete Concentric Collapse.11d ago